Difference between revisions of "Carcinoembryonic antigen"
Jump to navigation
Jump to search
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
[[Image:C-cell hyperplasia in MEN 2 - CEA -- very high mag.jpg|thumb|right|CEA immunostaining in C-cell hyperplasia. (WC)]] | [[Image:C-cell hyperplasia in MEN 2 - CEA -- very high mag.jpg|thumb|right|CEA immunostaining in [[C-cell hyperplasia]]. (WC)]] | ||
'''Carcinoembryonic antigen''', abbreviated '''CEA''', is set of glycoproteins present during fetal development and associated with the gastrointestinal tract. | '''Carcinoembryonic antigen''', abbreviated '''CEA''', is set of glycoproteins present during fetal development and associated with the gastrointestinal tract. | ||
In [[pathology]], they are associated with gastrointestinal tract tumours; however, may be seen in other tumours. | In [[pathology]], they are associated with gastrointestinal tract tumours; however, may be seen in other tumours. | ||
==Monoclonal & polyclonal== | |||
*Several different types of CEA antibodies are available. | |||
Broadly speaking they are divided into: | |||
*CEA-p = polyclonal CEA antibody. | |||
*CEA-m = monocloncal CEA antibody. | |||
The staining is dependent on the specific antibody,<ref name=pmid1695478>{{Cite journal | last1 = Sheahan | first1 = K. | last2 = O'Brien | first2 = MJ. | last3 = Burke | first3 = B. | last4 = Dervan | first4 = PA. | last5 = O'Keane | first5 = JC. | last6 = Gottlieb | first6 = LS. | last7 = Zamcheck | first7 = N. | title = Differential reactivities of carcinoembryonic antigen (CEA) and CEA-related monoclonal and polyclonal antibodies in common epithelial malignancies. | journal = Am J Clin Pathol | volume = 94 | issue = 2 | pages = 157-64 | month = Aug | year = 1990 | doi = | PMID = 1695478 }}</ref> as is generally true. | |||
==Positive== | ==Positive== | ||
*[[C-cell hyperplasia]]. | *[[C-cell hyperplasia]]. | ||
*[[Medullary thyroid carcinoma]]. | *[[Medullary thyroid carcinoma]]. | ||
*Eccrine glands of the [[skin]]. | |||
*[[Endocervical adenocarcinoma]] - CEA-m (25 +ve of 26 cases<ref>{{Cite journal | last1 = McCluggage | first1 = WG. | last2 = Sumathi | first2 = VP. | last3 = McBride | first3 = HA. | last4 = Patterson | first4 = A. | title = A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. | journal = Int J Gynecol Pathol | volume = 21 | issue = 1 | pages = 11-5 | month = Jan | year = 2002 | doi = | PMID = 11781517 }}</ref>). | |||
==See also== | ==See also== | ||
*[[Immunohistochemistry]]. | *[[Immunohistochemistry]]. | ||
==References== | |||
{{Reflist|1}} | |||
[[Category:Immunohistochemistry]] | [[Category:Immunohistochemistry]] | ||
Latest revision as of 12:18, 5 August 2016
CEA immunostaining in C-cell hyperplasia. (WC)
Carcinoembryonic antigen, abbreviated CEA, is set of glycoproteins present during fetal development and associated with the gastrointestinal tract.
In pathology, they are associated with gastrointestinal tract tumours; however, may be seen in other tumours.
Monoclonal & polyclonal
- Several different types of CEA antibodies are available.
Broadly speaking they are divided into:
- CEA-p = polyclonal CEA antibody.
- CEA-m = monocloncal CEA antibody.
The staining is dependent on the specific antibody,[1] as is generally true.
Positive
- C-cell hyperplasia.
- Medullary thyroid carcinoma.
- Eccrine glands of the skin.
- Endocervical adenocarcinoma - CEA-m (25 +ve of 26 cases[2]).
See also
References
- ↑ Sheahan, K.; O'Brien, MJ.; Burke, B.; Dervan, PA.; O'Keane, JC.; Gottlieb, LS.; Zamcheck, N. (Aug 1990). "Differential reactivities of carcinoembryonic antigen (CEA) and CEA-related monoclonal and polyclonal antibodies in common epithelial malignancies.". Am J Clin Pathol 94 (2): 157-64. PMID 1695478.
- ↑ McCluggage, WG.; Sumathi, VP.; McBride, HA.; Patterson, A. (Jan 2002). "A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas.". Int J Gynecol Pathol 21 (1): 11-5. PMID 11781517.